Tiago Girao

CIK: 0001618670

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (57.1%)

Position reduction

Option Exercises (M)1 (14.3%)

Derivative conversions

Awards (A)2 (28.6%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IMVT

Immunovant, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

IMVT
Immunovant, Inc.
Oct 28, 2026
Sale(S)
Direct
6.6K shares at avg. $28.50$188K
IMVT
Immunovant, Inc.
Jul 23, 2026
Sale(S)
Direct
6.8K shares at avg. $38.69$263K
IMVT
Immunovant, Inc.
Jun 26, 2026
Exercise(M)
Direct
10K shares at avg. $15.90$159K
IMVT
Immunovant, Inc.
Jun 26, 2026
Sale(S)
Direct
10K shares at avg. $38.46$385K
IMVT
Immunovant, Inc.
Apr 23, 2026
Sale(S)
Direct
25.8K shares at avg. $29.62$763K
IMVT
Immunovant, Inc.
Apr 7, 2026
Award(A)
Direct
65K shares-
IMVT
Immunovant, Inc.
May 1, 2025
Award(A)
Direct
208.4K shares-

		Type	Shares	Price		Ownership
Oct 28, 2026	IMVT Immunovant, Inc.	Sale(S)	6,606	$28.50	$188,271	Direct
Jul 23, 2026	IMVT Immunovant, Inc.	Sale(S)	6,798	$38.69	$263,015	Direct
Jun 26, 2026	IMVT Immunovant, Inc.	Exercise(M)	10,000	$15.90	$159,000	Direct
Jun 26, 2026	IMVT Immunovant, Inc.	Sale(S)	10,000	$38.46	$384,600	Direct
Apr 23, 2026	IMVT Immunovant, Inc.	Sale(S)	25,760	$29.62	$763,011	Direct
Apr 7, 2026	IMVT Immunovant, Inc.	Award(A)	64,968	-	$0	Direct
May 1, 2025	IMVT Immunovant, Inc.	Award(A)	208,388	-	-	Direct

1-7 of 7 transactions

About Girao Tiago

Girao Tiago (SEC CIK 0001618670) files insider reports with the SEC as Chief Financial Officer of Immunovant, Inc. (IMVT).

Signal8 holds 7 ownership filings by Girao Tiago (1 Form 3, 6 Form 4), filed between Apr 28, 2025 and Oct 30, 2026. Those filings report 7 transactions, from May 1, 2025 to Oct 28, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Girao Tiago's filings is in DURHAM, NC.

Recent filings by Girao Tiago

Oct 28, 2026: Open-market sale of IMVT shares (Form 4, code S).
Jul 23, 2026: Open-market sale of IMVT shares (Form 4, code S).
Jun 26, 2026: Option exercise of IMVT shares (Form 4, code M).
Jun 26, 2026: Open-market sale of IMVT shares (Form 4, code S).
Apr 23, 2026: Open-market sale of IMVT shares (Form 4, code S).

Other insiders filing for Immunovant, Inc. (IMVT)

Stout Jay S, Chief Technology Officer
Van Tuyl Christopher, Chief Legal Officer
Gloria Melanie, Chief Operating Officer
Venker Eric, Chief Executive Officer
Pande Atul, Director
Fromkin Andrew J., Director

How to read Form 4 transaction codes